Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cisplatin is a platinum-based chemotherapeutic agent that exerts its cytotoxic effects primarily by binding to DNA and forming various types of cross-links. These cross-links disrupt essential cellular processes such as DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis. The main types of crosslinks formed are intrastrand (most common), interstrand, and DNA-protein crosslinks. Cells rely on repair mechanisms like NER and the Fanconi anemia pathway to resolve these adducts.
Cisplatin binds to DNA, forming intrastrand and interstrand crosslinks, as well as DNA-protein crosslinks, which inhibit DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA (cisplatin-induced crosslinking).